Literature DB >> 27734262

Antibody-Based Treatment of Acute Myeloid Leukemia.

Phillip M Garfin1, Eric J Feldman2.   

Abstract

While antibody-based therapies have emerged as clinically effective approaches for several hematologic and solid malignancies, they have not played a significant role to date in the treatment of acute myeloid leukemia (AML). More recently, improvements in antibody-drug conjugate technology, bispecific antibodies, as well as identification of novel AML antigens have re-invigorated enthusiasm for antibody-based therapies for AML. This review describes experiences with former and existing antibody-based therapies for AML, including unconjugated antibodies, antibody-drug conjugates (ADCs), radio-labelled antibodies, and immune-engaging antibodies, and discusses the promise and challenges associated with each.

Entities:  

Keywords:  Acute myeloid leukemia; Antibody therapy; CD123; CD33; Immunotherapy

Mesh：

Substances：

Year:  2016        PMID： 27734262     DOI： 10.1007/s11899-016-0349-7

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  73 in total

1.  Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.

Authors:  Marc Buyse; Pierre Squifflet; Beverly J Lange; Todd A Alonzo; Richard A Larson; Jonathan E Kolitz; Stephen L George; Clara D Bloomfield; Sylvie Castaigne; Sylvie Chevret; Didier Blaise; Dominique Maraninchi; Kathryn J Lucchesi; Tomasz Burzykowski
Journal:  Blood       Date:  2011-04-25       Impact factor: 22.113

Review 2.  Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.

Authors:  Roland B Walter; Frederick R Appelbaum; Elihu H Estey; Irwin D Bernstein
Journal:  Blood       Date:  2012-01-27       Impact factor: 22.113

Review 3.  What happened to anti-CD33 therapy for acute myeloid leukemia?

Authors:  Joseph G Jurcic
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

Review 4.  Mylotarg: antibody-targeted chemotherapy comes of age.

Authors:  E L Sievers; M Linenberger
Journal:  Curr Opin Oncol       Date:  2001-11       Impact factor: 3.645

5.  Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease.

Authors:  A D Cohen; S M Luger; C Sickles; P A Mangan; D L Porter; S J Schuster; D E Tsai; S Nasta; A M Gewirtz; E A Stadtmauer
Journal:  Bone Marrow Transplant       Date:  2002-07       Impact factor: 5.483

Review 6.  Update on rational targeted therapy in AML.

Authors:  Danielle Shafer; Steven Grant
Journal:  Blood Rev       Date:  2016-02-22       Impact factor: 8.250

7.  Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia.

Authors:  Hua Lu; Quan Zhou; Vishal Deshmukh; Hardeep Phull; Jennifer Ma; Virginie Tardif; Rahul R Naik; Claire Bouvard; Yong Zhang; Seihyun Choi; Brian R Lawson; Shoutian Zhu; Chan Hyuk Kim; Peter G Schultz
Journal:  Angew Chem Int Ed Engl       Date:  2014-07-23       Impact factor: 15.336

8.  Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.

Authors:  J M Burke; P C Caron; E B Papadopoulos; C R Divgi; G Sgouros; K S Panageas; R D Finn; S M Larson; R J O'Reilly; D A Scheinberg; J G Jurcic
Journal:  Bone Marrow Transplant       Date:  2003-09       Impact factor: 5.483

9.  Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial.

Authors:  Sergio Amadori; Stefan Suciu; Dominik Selleslag; Franco Aversa; Gianluca Gaidano; Maurizio Musso; Luciana Annino; Adriano Venditti; Maria Teresa Voso; Carla Mazzone; Domenico Magro; Paolo De Fabritiis; Petra Muus; Giuliana Alimena; Marco Mancini; Anne Hagemeijer; Francesca Paoloni; Marco Vignetti; Paola Fazi; Liv Meert; Safaa Mahmoud Ramadan; Roel Willemze; Theo de Witte; Frédéric Baron
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544

10.  Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.

Authors:  Monique Terwijn; Wendelien Zeijlemaker; Angèle Kelder; Arjo P Rutten; Alexander N Snel; Willemijn J Scholten; Thomas Pabst; Gregor Verhoef; Bob Löwenberg; Sonja Zweegman; Gert J Ossenkoppele; Gerrit J Schuurhuis
Journal:  PLoS One       Date:  2014-09-22       Impact factor: 3.240
View more
  7 in total

Review 1.  Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.

Authors:  Cédric Rossi; Marie-Lorraine Chrétien; René-Olivier Casasnovas
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

2.  Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.

Authors:  Ying Chen; Fengtao You; Licui Jiang; Jialu Li; Xuejun Zhu; Yangyi Bao; Xiang Sun; Xiaowen Tang; Huimin Meng; Gangli An; Bozhen Zhang; Lin Yang
Journal:  Oncotarget       Date:  2017-06-06

3.  An immunological electrospun scaffold for tumor cell killing and healthy tissue regeneration.

Authors:  Xingzhi Liu; Hongbo Zhang; Ruoyu Cheng; Yanzheng Gu; Yin Yin; Zhiyong Sun; Guoqing Pan; Zhongbin Deng; Huilin Yang; Lianfu Deng; Wenguo Cui; Hélder A Santos; Qin Shi
Journal:  Mater Horiz       Date:  2018-08-16       Impact factor: 13.266

Review 4.  Immunotherapy in AML: a brief review on emerging strategies.

Authors:  A Moeinafshar; S Hemmati; N Rezaei
Journal:  Clin Transl Oncol       Date:  2021-06-23       Impact factor: 3.405

5.  CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping.

Authors:  Anne E Bras; Valerie de Haas; Arthur van Stigt; Mojca Jongen-Lavrencic; H Berna Beverloo; Jeroen G Te Marvelde; C Michel Zwaan; Jacques J M van Dongen; Jeanette H W Leusen; Vincent H J van der Velden
Journal:  Cytometry B Clin Cytom       Date:  2018-11-18       Impact factor: 3.058

Review 6.  A general view of CD33+ leukemic stem cells and CAR-T cells as interesting targets in acute myeloblatsic leukemia therapy.

Authors:  Ezzatollah Fathi; Raheleh Farahzadi; Roghayeh Sheervalilou; Zohreh Sanaat; Ilja Vietor
Journal:  Blood Res       Date:  2020-03-30

7.  Identification of Nanobodies against the Acute Myeloid Leukemia Marker CD33.

Authors:  Ema Romão; Ahmet Krasniqi; Laila Maes; Camille Vandenbrande; Yann G-J Sterckx; Benoit Stijlemans; Cécile Vincke; Nick Devoogdt; Serge Muyldermans
Journal:  Int J Mol Sci       Date:  2020-01-02       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.